Prospective Validation of a 21-Gene Expression Assay in Breast Cancer - PubMed (original) (raw)
Randomized Controlled Trial
. 2015 Nov 19;373(21):2005-14.
doi: 10.1056/NEJMoa1510764. Epub 2015 Sep 27.
Robert J Gray, Della F Makower, Kathleen I Pritchard, Kathy S Albain, Daniel F Hayes, Charles E Geyer Jr, Elizabeth C Dees, Edith A Perez, John A Olson Jr, JoAnne Zujewski, Tracy Lively, Sunil S Badve, Thomas J Saphner, Lynne I Wagner, Timothy J Whelan, Matthew J Ellis, Soonmyung Paik, William C Wood, Peter Ravdin, Maccon M Keane, Henry L Gomez Moreno, Pavan S Reddy, Timothy F Goggins, Ingrid A Mayer, Adam M Brufsky, Deborah L Toppmeyer, Virginia G Kaklamani, James N Atkins, Jeffrey L Berenberg, George W Sledge
Affiliations
- PMID: 26412349
- PMCID: PMC4701034
- DOI: 10.1056/NEJMoa1510764
Randomized Controlled Trial
Prospective Validation of a 21-Gene Expression Assay in Breast Cancer
Joseph A Sparano et al. N Engl J Med. 2015.
Abstract
Background: Prior studies with the use of a prospective-retrospective design including archival tumor samples have shown that gene-expression assays provide clinically useful prognostic information. However, a prospectively conducted study in a uniformly treated population provides the highest level of evidence supporting the clinical validity and usefulness of a biomarker.
Methods: We performed a prospective trial involving women with hormone-receptor-positive, human epidermal growth factor receptor type 2 (HER2)-negative, axillary node-negative breast cancer with tumors of 1.1 to 5.0 cm in the greatest dimension (or 0.6 to 1.0 cm in the greatest dimension and intermediate or high tumor grade) who met established guidelines for the consideration of adjuvant chemotherapy on the basis of clinicopathologic features. A reverse-transcriptase-polymerase-chain-reaction assay of 21 genes was performed on the paraffin-embedded tumor tissue, and the results were used to calculate a score indicating the risk of breast-cancer recurrence; patients were assigned to receive endocrine therapy without chemotherapy if they had a recurrence score of 0 to 10, indicating a very low risk of recurrence (on a scale of 0 to 100, with higher scores indicating a greater risk of recurrence).
Results: Of the 10,253 eligible women enrolled, 1626 women (15.9%) who had a recurrence score of 0 to 10 were assigned to receive endocrine therapy alone without chemotherapy. At 5 years, in this patient population, the rate of invasive disease-free survival was 93.8% (95% confidence interval [CI], 92.4 to 94.9), the rate of freedom from recurrence of breast cancer at a distant site was 99.3% (95% CI, 98.7 to 99.6), the rate of freedom from recurrence of breast cancer at a distant or local-regional site was 98.7% (95% CI, 97.9 to 99.2), and the rate of overall survival was 98.0% (95% CI, 97.1 to 98.6).
Conclusions: Among patients with hormone-receptor-positive, HER2-negative, axillary node-negative breast cancer who met established guidelines for the recommendation of adjuvant chemotherapy on the basis of clinicopathologic features, those with tumors that had a favorable gene-expression profile had very low rates of recurrence at 5 years with endocrine therapy alone. (Funded by the National Cancer Institute and others; ClinicalTrials.gov number, NCT00310180.).
Conflict of interest statement
No other potential conflict of interest relevant to this article was reported.
Figures
Figure 1. Kaplan–Meier Estimates in the Analyses of Invasive Disease–free Survival, Freedom from Recurrence of Breast Cancer at a Distant Site, Freedom from Recurrence at Any Site, and Overall Survival
A total of 1626 patients with a recurrence score of 0 to 10 (on a scale from 0 to 100, with higher scores indicating a greater risk of recurrence) were included in the analyses. In the time-to-event analysis of invasive disease–free survival, Panel A shows the probability of freedom from the first event of recurrence of ipsilateral breast tumor, local recurrence, regional recurrence, distant recurrence, contralateral second primary invasive cancer, second primary nonbreast invasive cancer (excluding nonmelanoma skin cancer), or death without evidence of recurrence (which corresponds to the standardized definitions for efficacy end points [STEEP] definition of invasive disease–free survival). In the time-to-event analysis of freedom from the recurrence of breast cancer at a distant site, Panel B shows the probability of freedom from the first event of distant recurrence of breast cancer or death with distant recurrence, if death was the first manifestation of distant recurrence (which corresponds to the STEEP definition of distant recurrence–free interval). In the time-to-event analysis of freedom from recurrence at any site, Panel C shows the probability of freedom from the first event of recurrence of breast cancer (ipsilateral breast cancer, local or regional recurrence, or distant recurrence) or the date of death with recurrence, if death was the first manifestation of recurrence (which corresponds to the STEEP definition of recurrence-free interval). Panel D shows the probability of overall survival in the time-to-event analysis. In each panel, dashed lines indicate 95% confidence intervals and the insets show the same data on an enlarged y axis.
Comment in
- Biology before Anatomy in Early Breast Cancer--Precisely the Point.
Hudis CA. Hudis CA. N Engl J Med. 2015 Nov 19;373(21):2079-80. doi: 10.1056/NEJMe1512092. Epub 2015 Sep 27. N Engl J Med. 2015. PMID: 26412350 No abstract available. - A 21-Gene Expression Assay in Breast Cancer.
Sparano JA. Sparano JA. N Engl J Med. 2016 Apr 7;374(14):1387. doi: 10.1056/NEJMc1515988. N Engl J Med. 2016. PMID: 27050216 No abstract available. - A 21-Gene Expression Assay in Breast Cancer.
Debled M, Tunon de Lara C, MacGrogran G. Debled M, et al. N Engl J Med. 2016 Apr 7;374(14):1385-6. doi: 10.1056/NEJMc1515988. N Engl J Med. 2016. PMID: 27050217 No abstract available. - A 21-Gene Expression Assay in Breast Cancer.
Foukakis T, Falato C, Bergh J. Foukakis T, et al. N Engl J Med. 2016 Apr 7;374(14):1386-7. doi: 10.1056/NEJMc1515988. N Engl J Med. 2016. PMID: 27050218 No abstract available.
Similar articles
- Adjuvant Chemotherapy Guided by a 21-Gene Expression Assay in Breast Cancer.
Sparano JA, Gray RJ, Makower DF, Pritchard KI, Albain KS, Hayes DF, Geyer CE Jr, Dees EC, Goetz MP, Olson JA Jr, Lively T, Badve SS, Saphner TJ, Wagner LI, Whelan TJ, Ellis MJ, Paik S, Wood WC, Ravdin PM, Keane MM, Gomez Moreno HL, Reddy PS, Goggins TF, Mayer IA, Brufsky AM, Toppmeyer DL, Kaklamani VG, Berenberg JL, Abrams J, Sledge GW Jr. Sparano JA, et al. N Engl J Med. 2018 Jul 12;379(2):111-121. doi: 10.1056/NEJMoa1804710. Epub 2018 Jun 3. N Engl J Med. 2018. PMID: 29860917 Free PMC article. Clinical Trial. - Clinical and Genomic Risk to Guide the Use of Adjuvant Therapy for Breast Cancer.
Sparano JA, Gray RJ, Ravdin PM, Makower DF, Pritchard KI, Albain KS, Hayes DF, Geyer CE Jr, Dees EC, Goetz MP, Olson JA Jr, Lively T, Badve SS, Saphner TJ, Wagner LI, Whelan TJ, Ellis MJ, Paik S, Wood WC, Keane MM, Gomez Moreno HL, Reddy PS, Goggins TF, Mayer IA, Brufsky AM, Toppmeyer DL, Kaklamani VG, Berenberg JL, Abrams J, Sledge GW Jr. Sparano JA, et al. N Engl J Med. 2019 Jun 20;380(25):2395-2405. doi: 10.1056/NEJMoa1904819. Epub 2019 Jun 3. N Engl J Med. 2019. PMID: 31157962 Free PMC article. Clinical Trial. - 21-Gene Assay to Inform Chemotherapy Benefit in Node-Positive Breast Cancer.
Kalinsky K, Barlow WE, Gralow JR, Meric-Bernstam F, Albain KS, Hayes DF, Lin NU, Perez EA, Goldstein LJ, Chia SKL, Dhesy-Thind S, Rastogi P, Alba E, Delaloge S, Martin M, Kelly CM, Ruiz-Borrego M, Gil-Gil M, Arce-Salinas CH, Brain EGC, Lee ES, Pierga JY, Bermejo B, Ramos-Vazquez M, Jung KH, Ferrero JM, Schott AF, Shak S, Sharma P, Lew DL, Miao J, Tripathy D, Pusztai L, Hortobagyi GN. Kalinsky K, et al. N Engl J Med. 2021 Dec 16;385(25):2336-2347. doi: 10.1056/NEJMoa2108873. Epub 2021 Dec 1. N Engl J Med. 2021. PMID: 34914339 Free PMC article. Clinical Trial. - Multigene testing in breast cancer: What have we learned from the 21-gene recurrence score assay?
Turashvili G, Wen HY. Turashvili G, et al. Breast J. 2020 Jun;26(6):1199-1207. doi: 10.1111/tbj.13859. Epub 2020 May 26. Breast J. 2020. PMID: 32458521 Review. - Recommendations from the European Commission Initiative on Breast Cancer for multigene testing to guide the use of adjuvant chemotherapy in patients with early breast cancer, hormone receptor positive, HER-2 negative.
Giorgi Rossi P, Lebeau A, Canelo-Aybar C, Saz-Parkinson Z, Quinn C, Langendam M, Mcgarrigle H, Warman S, Rigau D, Alonso-Coello P, Broeders M, Graewingholt A, Posso M, Duffy S, Schünemann HJ; ECIBC Contributor Group. Giorgi Rossi P, et al. Br J Cancer. 2021 Apr;124(9):1503-1512. doi: 10.1038/s41416-020-01247-z. Epub 2021 Feb 18. Br J Cancer. 2021. PMID: 33597715 Free PMC article. Review.
Cited by
- Dissection of triple-negative breast cancer microenvironment and identification of potential therapeutic drugs using single-cell RNA sequencing analysis.
Cheng W, Mi W, Wang S, Wang X, Jiang H, Chen J, Yang K, Jiang W, Ye J, Guo B, Zhang Y. Cheng W, et al. J Pharm Anal. 2024 Aug;14(8):100975. doi: 10.1016/j.jpha.2024.100975. Epub 2024 Apr 2. J Pharm Anal. 2024. PMID: 39263352 Free PMC article. - Validation of an AI-based solution for breast cancer risk stratification using routine digital histopathology images.
Sharma A, Lövgren SK, Eriksson KL, Wang Y, Robertson S, Hartman J, Rantalainen M. Sharma A, et al. Breast Cancer Res. 2024 Aug 14;26(1):123. doi: 10.1186/s13058-024-01879-6. Breast Cancer Res. 2024. PMID: 39143539 Free PMC article. - DNA Damage Response in Early Breast Cancer: A Phase III Cohort in the Phobos Study.
Krasniqi E, Ercolani C, Di Benedetto A, Di Lisa FS, Filomeno L, Arcuri T, Botti C, Pelle F, Cavicchi F, Cappelli S, Barba M, Pizzuti L, Maugeri-Saccà M, Moscetti L, Grassadonia A, Tinari N, Sanguineti G, Takanen S, Fragnito D, Terrenato I, Buglioni S, Perracchio L, Latorre A, De Maria R, Pallocca M, Ciliberto G, Giotta F, Vici P. Krasniqi E, et al. Cancers (Basel). 2024 Jul 23;16(15):2628. doi: 10.3390/cancers16152628. Cancers (Basel). 2024. PMID: 39123356 Free PMC article. - The impact of extensive intraductal component (EIC) on the genomic risk of recurrence in early hormone receptor positive breast cancer.
Bar Y, Bar K, Feldman D, Dror JB, Shahoha M, Lerner S, Shachar SS, Weiss-Meilik A, Dershowitz N, Wolf I, Sonnenblick A. Bar Y, et al. Breast. 2024 Oct;77:103777. doi: 10.1016/j.breast.2024.103777. Epub 2024 Jul 14. Breast. 2024. PMID: 39038425 Free PMC article. - Genomic signatures in breast cancer in a real-world setting: Experience in a Brazilian Northeastern Center.
Vieira SC, Dos Reis CA, Holanda MEF, da Silva Fontinele DR, Leal AIC, de Lima FT. Vieira SC, et al. Breast Dis. 2024;43(1):237-242. doi: 10.3233/BD-230044. Breast Dis. 2024. PMID: 38995764 Free PMC article.
References
- Jemal A, Center MM, DeSantis C, Ward EM. Global patterns of cancer incidence and mortality rates and trends. Cancer Epidemiol Biomarkers Prev. 2010;19:1893–1907. - PubMed
- Hayes D, Padnos SB. Predictive and prognostic markers in cancer. Clin Adv Hematol Oncol. 2011;9:130–132. - PubMed
- Wolff AC, Hammond ME, Hicks DG, et al. Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline update. J Clin Oncol. 2013;31:3997–4013. - PubMed
- Mansour EG, Gray R, Shatila AH, et al. Efficacy of adjuvant chemotherapy in high-risk node-negative breast cancer: an intergroup study. N Engl J Med. 1989;320:485–490. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
- CA189804/CA/NCI NIH HHS/United States
- CA189869/CA/NCI NIH HHS/United States
- U10 CA086802/CA/NCI NIH HHS/United States
- U10 CA037403/CA/NCI NIH HHS/United States
- CA180801/CA/NCI NIH HHS/United States
- CA180857/CA/NCI NIH HHS/United States
- U10 CA180868/CA/NCI NIH HHS/United States
- CA180847/CA/NCI NIH HHS/United States
- UG1 CA189804/CA/NCI NIH HHS/United States
- CA180822/CA/NCI NIH HHS/United States
- UG1 CA233270/CA/NCI NIH HHS/United States
- UG1 CA189867/CA/NCI NIH HHS/United States
- CA189858/CA/NCI NIH HHS/United States
- CA180795/CA/NCI NIH HHS/United States
- UG1 CA190140/CA/NCI NIH HHS/United States
- CA180833/CA/NCI NIH HHS/United States
- U10 CA077202/CA/NCI NIH HHS/United States
- CA077202/CA/NCI NIH HHS/United States
- U10 CA021115/CA/NCI NIH HHS/United States
- P30 CA047904/CA/NCI NIH HHS/United States
- UG1 CA189859/CA/NCI NIH HHS/United States
- UG1 CA189869/CA/NCI NIH HHS/United States
- CA180820/CA/NCI NIH HHS/United States
- U24 CA196172/CA/NCI NIH HHS/United States
- U10 CA180821/CA/NCI NIH HHS/United States
- U10 CA180801/CA/NCI NIH HHS/United States
- P50 CA121973/CA/NCI NIH HHS/United States
- U10 CA180795/CA/NCI NIH HHS/United States
- U10 CA066636/CA/NCI NIH HHS/United States
- UG1 CA189858/CA/NCI NIH HHS/United States
- U10 CA180857/CA/NCI NIH HHS/United States
- U10 CA180847/CA/NCI NIH HHS/United States
- CA190140/CA/NCI NIH HHS/United States
- U10 CA180790/CA/NCI NIH HHS/United States
- CA180838/CA/NCI NIH HHS/United States
- CA180794/CA/NCI NIH HHS/United States
- CA189867/CA/NCI NIH HHS/United States
- U10 CA180820/CA/NCI NIH HHS/United States
- U10 CA023318/CA/NCI NIH HHS/United States
- U10 CA180833/CA/NCI NIH HHS/United States
- CA180790/CA/NCI NIH HHS/United States
- UG1 CA189808/CA/NCI NIH HHS/United States
- CA180888/CA/NCI NIH HHS/United States
- U10 CA180794/CA/NCI NIH HHS/United States
- CA180816/CA/NCI NIH HHS/United States
- CA189859/CA/NCI NIH HHS/United States
- CA180868/CA/NCI NIH HHS/United States
- CA180844/CA/NCI NIH HHS/United States
- U10 CA180799/CA/NCI NIH HHS/United States
- U10 CA180838/CA/NCI NIH HHS/United States
- P30 CA013330/CA/NCI NIH HHS/United States
- CA180864/CA/NCI NIH HHS/United States
- CA180821/CA/NCI NIH HHS/United States
- U10 CA180888/CA/NCI NIH HHS/United States
- CA180799/CA/NCI NIH HHS/United States
- U10 CA180822/CA/NCI NIH HHS/United States
- U10 CA180816/CA/NCI NIH HHS/United States
- U10 CA180844/CA/NCI NIH HHS/United States
- U10 CA180864/CA/NCI NIH HHS/United States
- CA189808/CA/NCI NIH HHS/United States
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials
Miscellaneous